Decision

Early access to medicines scheme (EAMS) scientific opinion: nivolumab for non-squamous non-small cell lung cancer (NSCLC)

This publication was withdrawn on

The EAMS opinion for nivolumab for non-squamous non-small cell lung cancer (NSCLC) has been withdrawn as the marketing authorisation has been adopted by the European Commission.

Information on the EAMS scientific opinion given to nivolumab for non-squamous non-small cell lung cancer (NSCLC), including the public assessment report.